Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia
Tóm tắt
This study on serum ferritin levels ind urinary iron excretion after 12h subcutaneous infusion of desferrioxamine in 10 thalassemia intermedia patients shows that even nontransfusion-dependent patients may have positive iron balance resulting in iron overload from 5 years of age. However, the iron overload found in these patients appears to be much lower than in age matched patients with transfusion-dependent thalassemia major. Iron overload increases with advancing age, as shown by increasing serum ferritin levels and desferrioxamine-induced urinary iron elimination. After a six month trial of 12h continuous subcutaneous desferrioxamine administration there was a significant decline in serum ferritin levels. From this study it seems that iron chelation is indicated in thalassemia intermedia patients over 5 years of age in order to prevent iron accumulation. However, the appropriate treatment schedule should be tailored to the individual needs of each patients, established by close monitoring of serum ferritin levels and desferrioxamine-induced urinary iron elimination.
Tài liệu tham khảo
Cohen A, Schwartz E (1978) Iron chelation therapy with deferoxamine in Cooley anemia. J Pediat 92:643
Cumming RLC, Millar JA, Smith JA, Golderberg A (1969) Clinical and laboratory studies on the action of desferrioxamine. Br J Haematol 17:257
Erlandson ME, Brilliant R, Smith CA (1964) Comparison of sixty-six patients with thalassemia major and thirteen patients with thalassemia intermedia: including evaluations of growth, development, maturation and prognosis. Ann NY Academy of Sci 119:727
Graziano JH, Markenson A, Miller DR, Chang H, Bestak M, Meyer P, Piscotto P, Riflind A (1978) Chelation therapy in β-thalassemia major. I. Intravenous and subcutaneous deferoxamine. J Pediat 92:648
Graziano JM, Grady R, Cerami A (1974) The identification of 2–3 dihydroxybenzoic acid as a potentially useful iron chelating drug. J Pharmacol Experiment Therapeut 190:570
Huisman THJ, Schroeder WA, Brodie An, Mayson SM, Jakway J (1975) Microchromatography of hemoglobins. III. A simplified procedure for determination of hemoglobin A2. J Lab Clin Med 86:700
Hussain MAM, Green N, Flynn DM, Hussein S, Hoffbrand AV (1976) Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 2:1278
Kan YW, Schwartz F, Nathan DG (1968) Globin chain synthesis in the alpha thalassemia syndromes. J Clin Invest 47:2515
Modell B (1979) Advances in the use of iron-chelating agents for the treatment of iron overload. Progress in hematology (ed Brown EB, Vol XI, pp 267–312
Pembrey ME, MacWade P, Weatherall DJ (1972) Reliable routine estimation of small amount of foetal hemoglobin by alkalie denaturation. J Clin Pathol 25:738
Pippard MJ, Warner GT, Callender ST, Weatherall DJ (1979) Iron absorption and loading in β-thalassemia intermedia. Lancet 2:819
Propper DR, Cooper B, Rufo R, Nienhuis AW, Anderson WF, Bunn FH, Rosenthal A, Nathan DG (1977) Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 297:418
Weatherall DJ, Clegg JB (1972) The thalassaemia syndromes. 2nd edn. Oxford, Blackwell Scientific Publications
Weiner M, Karpatkin M, Hart D, Seaman C, Nora SK, Henry WL, Piomelli S (1978) Cooley anemia: high transfusion regimen and chelation therapy, results and perspective. J Pediat 92:653